JP7462951B2 - Ｊａｋ阻害剤 - Google Patents
Ｊａｋ阻害剤 Download PDFInfo
- Publication number
- JP7462951B2 JP7462951B2 JP2020550114A JP2020550114A JP7462951B2 JP 7462951 B2 JP7462951 B2 JP 7462951B2 JP 2020550114 A JP2020550114 A JP 2020550114A JP 2020550114 A JP2020550114 A JP 2020550114A JP 7462951 B2 JP7462951 B2 JP 7462951B2
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- pyrrolo
- pyrimidin
- amino
- azaspiro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229940122245 Janus kinase inhibitor Drugs 0.000 title description 7
- 150000001875 compounds Chemical class 0.000 claims description 77
- -1 cyano, hydroxy Chemical group 0.000 claims description 44
- 125000000217 alkyl group Chemical group 0.000 claims description 34
- 239000000203 mixture Substances 0.000 claims description 27
- 125000001072 heteroaryl group Chemical group 0.000 claims description 21
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 20
- 125000000623 heterocyclic group Chemical group 0.000 claims description 19
- 125000003118 aryl group Chemical group 0.000 claims description 17
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims description 17
- 150000002367 halogens Chemical class 0.000 claims description 12
- MAJSKCSJMXOCDA-UHFFFAOYSA-N N-(3-methoxy-1,2,4-thiadiazol-5-yl)-9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3-azaspiro[5.5]undecane-3-carboxamide Chemical compound COC1=NSC(NC(=O)N2CCC3(CCC(CC3)N(C)C3=NC=NC4=C3C=CN4)CC2)=N1 MAJSKCSJMXOCDA-UHFFFAOYSA-N 0.000 claims description 11
- 125000003342 alkenyl group Chemical group 0.000 claims description 11
- 125000000304 alkynyl group Chemical group 0.000 claims description 11
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 125000004104 aryloxy group Chemical group 0.000 claims description 9
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- CKJNUZNMWOVDFN-UHFFFAOYSA-N methanone Chemical compound O=[CH-] CKJNUZNMWOVDFN-UHFFFAOYSA-N 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 7
- 125000005356 cycloalkylalkenyl group Chemical group 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- 125000004946 alkenylalkyl group Chemical group 0.000 claims description 6
- 125000005038 alkynylalkyl group Chemical group 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- ZIYSPMNEUWSHNT-UHFFFAOYSA-N tert-butyl 9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3-azaspiro[5.5]undecane-3-carboxylate Chemical compound CN(C1CCC2(CCN(CC2)C(=O)OC(C)(C)C)CC1)C=1C2=C(N=CN=1)NC=C2 ZIYSPMNEUWSHNT-UHFFFAOYSA-N 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 5
- 208000027866 inflammatory disease Diseases 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- ICLZZFBCSCMVAR-UHFFFAOYSA-N 2-fluoro-4-[6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptane-2-carbonyl]benzonitrile Chemical compound FC1=C(C#N)C=CC(=C1)C(=O)N1CC2(C1)CC(C2)N(C=1C2=C(N=CN=1)NC=C2)C ICLZZFBCSCMVAR-UHFFFAOYSA-N 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- LZTVLJMNGXVCJP-UHFFFAOYSA-N 2,5-difluoro-4-[6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptane-2-carbonyl]benzonitrile Chemical compound FC1=C(C#N)C=C(C(=C1)C(=O)N1CC2(C1)CC(C2)N(C=1C2=C(N=CN=1)NC=C2)C)F LZTVLJMNGXVCJP-UHFFFAOYSA-N 0.000 claims description 3
- AXFIKTLVDGBLEH-UHFFFAOYSA-N 2-methoxy-1-[9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3-azaspiro[5.5]undecan-3-yl]ethanone Chemical compound COCC(=O)N1CCC2(CC1)CCC(CC2)N(C=1C2=C(N=CN=1)NC=C2)C AXFIKTLVDGBLEH-UHFFFAOYSA-N 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- FKHQJSSTWDXZTM-UHFFFAOYSA-N N-(3-cyanophenyl)-9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3-azaspiro[5.5]undecane-3-carboxamide Chemical compound C(#N)C=1C=C(C=CC=1)NC(=O)N1CCC2(CC1)CCC(CC2)N(C=1C2=C(N=CN=1)NC=C2)C FKHQJSSTWDXZTM-UHFFFAOYSA-N 0.000 claims description 3
- HBKQBGKLUWNWGO-UHFFFAOYSA-N N-(5-methoxy-[1,3]thiazolo[5,4-b]pyridin-2-yl)-9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3-azaspiro[5.5]undecane-3-carboxamide Chemical compound COC1=CC=C2C(=N1)SC(=N2)NC(=O)N1CCC2(CC1)CCC(CC2)N(C=1C2=C(N=CN=1)NC=C2)C HBKQBGKLUWNWGO-UHFFFAOYSA-N 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 125000004043 oxo group Chemical group O=* 0.000 claims description 3
- 125000006413 ring segment Chemical group 0.000 claims description 3
- 239000012453 solvate Substances 0.000 claims description 3
- SCKAIBAFHJVEKP-UHFFFAOYSA-N (1-cyclopropylpyrazol-4-yl)-[6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptan-2-yl]methanone Chemical compound C1(CC1)N1N=CC(=C1)C(=O)N1CC2(C1)CC(C2)N(C=1C2=C(N=CN=1)NC=C2)C SCKAIBAFHJVEKP-UHFFFAOYSA-N 0.000 claims description 2
- MHBGPFZMKMLBPP-UHFFFAOYSA-N (1-methylbenzimidazol-5-yl)-[6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptan-2-yl]methanone Chemical compound CN(C1CC2(CN(C2)C(=O)C2=CC3=C(N(C=N3)C)C=C2)C1)C=1C2=C(N=CN=1)NC=C2 MHBGPFZMKMLBPP-UHFFFAOYSA-N 0.000 claims description 2
- KDOUHIDUYPIERE-UHFFFAOYSA-N (1-methylpyrazol-3-yl)-[6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptan-2-yl]methanone Chemical compound CN(C1CC2(CN(C2)C(=O)C2=NN(C=C2)C)C1)C=1C2=C(N=CN=1)NC=C2 KDOUHIDUYPIERE-UHFFFAOYSA-N 0.000 claims description 2
- PWXMZODMDSDALW-UHFFFAOYSA-N (2-chloro-4-ethynylphenyl)-[6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptan-2-yl]methanone Chemical compound ClC1=C(C=CC(=C1)C#C)C(=O)N1CC2(C1)CC(C2)N(C=1C2=C(N=CN=1)NC=C2)C PWXMZODMDSDALW-UHFFFAOYSA-N 0.000 claims description 2
- VTSWOGVBFUOALQ-UHFFFAOYSA-N (3-chloro-4-ethynylphenyl)-[6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptan-2-yl]methanone Chemical compound ClC=1C=C(C=CC=1C#C)C(=O)N1CC2(C1)CC(C2)N(C=1C2=C(N=CN=1)NC=C2)C VTSWOGVBFUOALQ-UHFFFAOYSA-N 0.000 claims description 2
- RFVNRLAFSGMICN-UHFFFAOYSA-N (4-cyclopropylphenyl)-[6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptan-2-yl]methanone Chemical compound C1(CC1)C1=CC=C(C=C1)C(=O)N1CC2(C1)CC(C2)N(C=1C2=C(N=CN=1)NC=C2)C RFVNRLAFSGMICN-UHFFFAOYSA-N 0.000 claims description 2
- SYEBSJPGKYOMAM-UHFFFAOYSA-N (4-ethynyl-2-fluorophenyl)-[6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptan-2-yl]methanone Chemical compound C(#C)C1=CC(=C(C=C1)C(=O)N1CC2(C1)CC(C2)N(C=1C2=C(N=CN=1)NC=C2)C)F SYEBSJPGKYOMAM-UHFFFAOYSA-N 0.000 claims description 2
- HXXFJRPERSMFEY-UHFFFAOYSA-N (4-ethynyl-3-fluorophenyl)-[6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptan-2-yl]methanone Chemical compound C(#C)C1=C(C=C(C=C1)C(=O)N1CC2(C1)CC(C2)N(C=1C2=C(N=CN=1)NC=C2)C)F HXXFJRPERSMFEY-UHFFFAOYSA-N 0.000 claims description 2
- XEWXOOHHBJIIOR-UHFFFAOYSA-N (4-ethynyl-3-methylphenyl)-[6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptan-2-yl]methanone Chemical compound C(#C)C1=C(C=C(C=C1)C(=O)N1CC2(C1)CC(C2)N(C=1C2=C(N=CN=1)NC=C2)C)C XEWXOOHHBJIIOR-UHFFFAOYSA-N 0.000 claims description 2
- BDSKVGUUSAYPRB-UHFFFAOYSA-N (4-ethynylphenyl)-[6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptan-2-yl]methanone Chemical compound C(#C)C1=CC=C(C=C1)C(=O)N1CC2(C1)CC(C2)N(C=1C2=C(N=CN=1)NC=C2)C BDSKVGUUSAYPRB-UHFFFAOYSA-N 0.000 claims description 2
- ACIWCZXRCJUFNJ-UHFFFAOYSA-N (4-fluorophenyl)-[6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptan-2-yl]methanone Chemical compound FC1=CC=C(C=C1)C(=O)N1CC2(C1)CC(C2)N(C=1C2=C(N=CN=1)NC=C2)C ACIWCZXRCJUFNJ-UHFFFAOYSA-N 0.000 claims description 2
- VDMHFPIUPATQGC-UHFFFAOYSA-N (4-iodophenyl)-[6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptan-2-yl]methanone Chemical compound IC1=CC=C(C=C1)C(=O)N1CC2(C1)CC(C2)N(C=1C2=C(N=CN=1)NC=C2)C VDMHFPIUPATQGC-UHFFFAOYSA-N 0.000 claims description 2
- GOGIWXFYUZLPET-UHFFFAOYSA-N (4-methoxyphenyl)-[6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptan-2-yl]methanone Chemical compound COC1=CC=C(C=C1)C(=O)N1CC2(C1)CC(C2)N(C=1C2=C(N=CN=1)NC=C2)C GOGIWXFYUZLPET-UHFFFAOYSA-N 0.000 claims description 2
- JXJSEMWPILAPKS-UHFFFAOYSA-N (5-chloropyridin-2-yl)-[6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptan-2-yl]methanone Chemical compound ClC=1C=CC(=NC=1)C(=O)N1CC2(C1)CC(C2)N(C=1C2=C(N=CN=1)NC=C2)C JXJSEMWPILAPKS-UHFFFAOYSA-N 0.000 claims description 2
- BQCZJRSLRYZMGG-UHFFFAOYSA-N (5-ethynylpyridin-2-yl)-[6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptan-2-yl]methanone Chemical compound C(#C)C=1C=CC(=NC=1)C(=O)N1CC2(C1)CC(C2)N(C=1C2=C(N=CN=1)NC=C2)C BQCZJRSLRYZMGG-UHFFFAOYSA-N 0.000 claims description 2
- NWQMLXUIWUYHSD-UHFFFAOYSA-N 1-[6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptan-2-yl]-3-methylsulfonylpropan-1-one Chemical compound CN(C1CC2(C1)CN(C2)C(=O)CCS(C)(=O)=O)C1=NC=NC2=C1C=CN2 NWQMLXUIWUYHSD-UHFFFAOYSA-N 0.000 claims description 2
- DJJQOGRNMXRGGR-UHFFFAOYSA-N 1-[6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptan-2-yl]propan-1-one Chemical compound CCC(=O)N1CC2(CC(C2)N(C)C2=NC=NC3=C2C=CN3)C1 DJJQOGRNMXRGGR-UHFFFAOYSA-N 0.000 claims description 2
- BYISEBGOLCFZQT-UHFFFAOYSA-N 1-[6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptane-2-carbonyl]cyclopropane-1-carbonitrile Chemical compound CN(C1CC2(CN(C2)C(=O)C2(CC2)C#N)C1)C=1C2=C(N=CN=1)NC=C2 BYISEBGOLCFZQT-UHFFFAOYSA-N 0.000 claims description 2
- KTOPVQNYKABUFY-UHFFFAOYSA-N 1-[9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3-azaspiro[5.5]undecan-3-yl]-3-methylsulfonylpropan-1-one Chemical compound CS(=O)(=O)CCC(=O)N1CCC2(CC1)CCC(CC2)N(C=1C2=C(N=CN=1)NC=C2)C KTOPVQNYKABUFY-UHFFFAOYSA-N 0.000 claims description 2
- VQVZSMAERXBLDB-UHFFFAOYSA-N 1-[9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3-azaspiro[5.5]undecan-3-yl]butan-1-one Chemical compound CCCC(=O)N1CCC2(CCC(CC2)N(C)C2=NC=NC3=C2C=CN3)CC1 VQVZSMAERXBLDB-UHFFFAOYSA-N 0.000 claims description 2
- QIQHXWYVKFNQFY-UHFFFAOYSA-N 1-[9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3-azaspiro[5.5]undecan-3-yl]ethanone Chemical compound CN(C1CCC2(CC1)CCN(CC2)C(C)=O)C1=NC=NC2=C1C=CN2 QIQHXWYVKFNQFY-UHFFFAOYSA-N 0.000 claims description 2
- HOSLAXOWUINHCU-UHFFFAOYSA-N 1-[9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3-azaspiro[5.5]undecan-3-yl]propan-1-one Chemical compound CCC(=O)N1CCC2(CCC(CC2)N(C)C2=NC=NC3=C2C=CN3)CC1 HOSLAXOWUINHCU-UHFFFAOYSA-N 0.000 claims description 2
- KBSLNJCFOFKELT-UHFFFAOYSA-N 1-[9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3-azaspiro[5.5]undecane-3-carbonyl]cyclopropane-1-carbonitrile Chemical compound CN(C1CCC2(CC1)CCN(CC2)C(=O)C1(CC1)C#N)C1=NC=NC2=C1C=CN2 KBSLNJCFOFKELT-UHFFFAOYSA-N 0.000 claims description 2
- WGUFUQJTJYOKEA-UHFFFAOYSA-N 1-benzothiophen-2-yl-[6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptan-2-yl]methanone Chemical compound S1C2=C(C=C1C(=O)N1CC3(C1)CC(C3)N(C=1C3=C(N=CN=1)NC=C3)C)C=CC=C2 WGUFUQJTJYOKEA-UHFFFAOYSA-N 0.000 claims description 2
- YALQZUKOTYNTOB-UHFFFAOYSA-N 1-benzothiophen-3-yl-[6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptan-2-yl]methanone Chemical compound S1C2=C(C(=C1)C(=O)N1CC3(C1)CC(C3)N(C=1C3=C(N=CN=1)NC=C3)C)C=CC=C2 YALQZUKOTYNTOB-UHFFFAOYSA-N 0.000 claims description 2
- GNXWZXKARIZRDO-UHFFFAOYSA-N 1-benzothiophen-3-yl-[9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3-azaspiro[5.5]undecan-3-yl]methanone Chemical compound S1C2=C(C(=C1)C(=O)N1CCC3(CC1)CCC(CC3)N(C=1C3=C(N=CN=1)NC=C3)C)C=CC=C2 GNXWZXKARIZRDO-UHFFFAOYSA-N 0.000 claims description 2
- RWBUQPKAOQVURL-UHFFFAOYSA-N 1H-indol-2-yl-[6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptan-2-yl]methanone Chemical compound N1C(=CC2=CC=CC=C12)C(=O)N1CC2(C1)CC(C2)N(C=1C2=C(N=CN=1)NC=C2)C RWBUQPKAOQVURL-UHFFFAOYSA-N 0.000 claims description 2
- GFIMPHQJSLXSME-UHFFFAOYSA-N 1H-indol-2-yl-[9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3-azaspiro[5.5]undecan-3-yl]methanone Chemical compound N1C(=CC2=CC=CC=C12)C(=O)N1CCC2(CC1)CCC(CC2)N(C=1C2=C(N=CN=1)NC=C2)C GFIMPHQJSLXSME-UHFFFAOYSA-N 0.000 claims description 2
- ZHIJLYUJVZKCDE-UHFFFAOYSA-N 2,2,2-trifluoroethyl 9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3-azaspiro[5.5]undecane-3-carboxylate Chemical compound CN(C1CCC2(CCN(CC2)C(=O)OCC(F)(F)F)CC1)C=1C2=C(N=CN=1)NC=C2 ZHIJLYUJVZKCDE-UHFFFAOYSA-N 0.000 claims description 2
- VWKRQZISFUNTGH-UHFFFAOYSA-N 2,3-dichloro-4-[6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptane-2-carbonyl]benzonitrile Chemical compound ClC1=C(C#N)C=CC(=C1Cl)C(=O)N1CC2(C1)CC(C2)N(C=1C2=C(N=CN=1)NC=C2)C VWKRQZISFUNTGH-UHFFFAOYSA-N 0.000 claims description 2
- SCAXMDURHTXFCQ-UHFFFAOYSA-N 2,3-difluoro-4-[2-[9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3-azaspiro[5.5]undecan-3-yl]-2-oxoethoxy]benzonitrile Chemical compound FC1=C(C#N)C=CC(=C1F)OCC(=O)N1CCC2(CC1)CCC(CC2)N(C=1C2=C(N=CN=1)NC=C2)C SCAXMDURHTXFCQ-UHFFFAOYSA-N 0.000 claims description 2
- JPRZCHJAVZPIMR-FIBGUPNXSA-N 2,3-difluoro-4-[6-[7H-pyrrolo[2,3-d]pyrimidin-4-yl(trideuteriomethyl)amino]-2-azaspiro[3.3]heptane-2-carbonyl]benzonitrile Chemical compound FC1=C(C#N)C=CC(=C1F)C(=O)N1CC2(C1)CC(C2)N(C=1C2=C(N=CN=1)NC=C2)C([2H])([2H])[2H] JPRZCHJAVZPIMR-FIBGUPNXSA-N 0.000 claims description 2
- JPRZCHJAVZPIMR-UHFFFAOYSA-N 2,3-difluoro-4-[6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptane-2-carbonyl]benzonitrile Chemical compound FC1=C(C#N)C=CC(=C1F)C(=O)N1CC2(C1)CC(C2)N(C=1C2=C(N=CN=1)NC=C2)C JPRZCHJAVZPIMR-UHFFFAOYSA-N 0.000 claims description 2
- IPSDQRYFGZNDAI-UHFFFAOYSA-N 2,3-difluoro-5-[6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptane-2-carbonyl]benzonitrile Chemical compound FC1=C(C#N)C=C(C=C1F)C(=O)N1CC2(C1)CC(C2)N(C=1C2=C(N=CN=1)NC=C2)C IPSDQRYFGZNDAI-UHFFFAOYSA-N 0.000 claims description 2
- DHAMPVOMGNQDBV-UHFFFAOYSA-N 2,6-difluoro-4-[6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptane-2-carbonyl]benzonitrile Chemical compound FC1=C(C#N)C(=CC(=C1)C(=O)N1CC2(C1)CC(C2)N(C=1C2=C(N=CN=1)NC=C2)C)F DHAMPVOMGNQDBV-UHFFFAOYSA-N 0.000 claims description 2
- LONSYRTYSIAVGT-UHFFFAOYSA-N 2-(1H-indol-3-yl)-1-[9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3-azaspiro[5.5]undecan-3-yl]ethanone Chemical compound N1C=C(C2=CC=CC=C12)CC(=O)N1CCC2(CC1)CCC(CC2)N(C=1C2=C(N=CN=1)NC=C2)C LONSYRTYSIAVGT-UHFFFAOYSA-N 0.000 claims description 2
- NACSANRBZILLPK-UHFFFAOYSA-N 2-(methylamino)-1-[9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3-azaspiro[5.5]undecan-3-yl]ethanone Chemical compound CNCC(=O)N1CCC2(CC1)CCC(CC2)N(C=1C2=C(N=CN=1)NC=C2)C NACSANRBZILLPK-UHFFFAOYSA-N 0.000 claims description 2
- HSYDZNMQTUSVAM-UHFFFAOYSA-N 2-chloro-4-[6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptane-2-carbonyl]benzonitrile Chemical compound ClC1=C(C#N)C=CC(=C1)C(=O)N1CC2(C1)CC(C2)N(C=1C2=C(N=CN=1)NC=C2)C HSYDZNMQTUSVAM-UHFFFAOYSA-N 0.000 claims description 2
- YCOCIGKZDUMCMK-UHFFFAOYSA-N 2-fluoro-4-[2-[9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3-azaspiro[5.5]undecan-3-yl]-2-oxoethoxy]benzonitrile Chemical compound FC1=C(C#N)C=CC(=C1)OCC(=O)N1CCC2(CC1)CCC(CC2)N(C=1C2=C(N=CN=1)NC=C2)C YCOCIGKZDUMCMK-UHFFFAOYSA-N 0.000 claims description 2
- XQCMLCLKZDEXCQ-UHFFFAOYSA-N 2-fluoro-4-[9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3-azaspiro[5.5]undecane-3-carbonyl]benzonitrile Chemical compound FC1=C(C#N)C=CC(=C1)C(=O)N1CCC2(CC1)CCC(CC2)N(C=1C2=C(N=CN=1)NC=C2)C XQCMLCLKZDEXCQ-UHFFFAOYSA-N 0.000 claims description 2
- ZKVWEDANSGSWPD-UHFFFAOYSA-N 2-fluoro-5-[6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptane-2-carbonyl]benzonitrile Chemical compound FC1=C(C#N)C=C(C=C1)C(=O)N1CC2(C1)CC(C2)N(C=1C2=C(N=CN=1)NC=C2)C ZKVWEDANSGSWPD-UHFFFAOYSA-N 0.000 claims description 2
- PVDXJOHUPFBJLL-UHFFFAOYSA-N 2-hydroxy-1-[6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptan-2-yl]ethanone Chemical compound OCC(=O)N1CC2(C1)CC(C2)N(C=1C2=C(N=CN=1)NC=C2)C PVDXJOHUPFBJLL-UHFFFAOYSA-N 0.000 claims description 2
- OXQAFIPYGXVTEI-UHFFFAOYSA-N 2-methyl-4-[6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptane-2-carbonyl]benzonitrile Chemical compound CC1=C(C#N)C=CC(=C1)C(=O)N1CC2(C1)CC(C2)N(C=1C2=C(N=CN=1)NC=C2)C OXQAFIPYGXVTEI-UHFFFAOYSA-N 0.000 claims description 2
- DXWXXMLXNSSPGK-UHFFFAOYSA-N 3,4-difluoro-5-[6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptane-2-carbonyl]benzonitrile Chemical compound FC=1C=C(C#N)C=C(C=1F)C(=O)N1CC2(C1)CC(C2)N(C=1C2=C(N=CN=1)NC=C2)C DXWXXMLXNSSPGK-UHFFFAOYSA-N 0.000 claims description 2
- TVBKULHUOUDGIL-UHFFFAOYSA-N 3,5-difluoro-4-[6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptane-2-carbonyl]benzonitrile Chemical compound FC=1C=C(C#N)C=C(C=1C(=O)N1CC2(C1)CC(C2)N(C=1C2=C(N=CN=1)NC=C2)C)F TVBKULHUOUDGIL-UHFFFAOYSA-N 0.000 claims description 2
- QEAYNZFIPVTVML-UHFFFAOYSA-N 3-[2-[9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3-azaspiro[5.5]undecan-3-yl]-2-oxoethoxy]benzonitrile Chemical compound CN(C1CCC2(CCN(CC2)C(COC=2C=C(C#N)C=CC=2)=O)CC1)C=1C2=C(N=CN=1)NC=C2 QEAYNZFIPVTVML-UHFFFAOYSA-N 0.000 claims description 2
- UYAIPRMOKFAMMH-UHFFFAOYSA-N 3-[6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptan-2-yl]-3-oxopropanenitrile Chemical compound CN(C1CC2(CN(C2)C(CC#N)=O)C1)C=1C2=C(N=CN=1)NC=C2 UYAIPRMOKFAMMH-UHFFFAOYSA-N 0.000 claims description 2
- YPBRWUQWYVFATN-UHFFFAOYSA-N 3-[6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptane-2-carbonyl]benzonitrile Chemical compound CN(C1CC2(CN(C2)C(=O)C=2C=C(C#N)C=CC=2)C1)C=1C2=C(N=CN=1)NC=C2 YPBRWUQWYVFATN-UHFFFAOYSA-N 0.000 claims description 2
- NDUWLZCWAXNXLO-UHFFFAOYSA-N 3-[9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3-azaspiro[5.5]undecane-3-carbonyl]benzonitrile Chemical compound CN(C1CCC2(CCN(CC2)C(=O)C=2C=C(C#N)C=CC=2)CC1)C=1C2=C(N=CN=1)NC=C2 NDUWLZCWAXNXLO-UHFFFAOYSA-N 0.000 claims description 2
- LIHKTTMDMZLSRS-UHFFFAOYSA-N 3-chloro-4-[6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptane-2-carbonyl]benzonitrile Chemical compound ClC=1C=C(C#N)C=CC=1C(=O)N1CC2(C1)CC(C2)N(C=1C2=C(N=CN=1)NC=C2)C LIHKTTMDMZLSRS-UHFFFAOYSA-N 0.000 claims description 2
- JFZIQIRABHLLKM-UHFFFAOYSA-N 3-fluoro-4-[6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptane-2-carbonyl]benzonitrile Chemical compound FC=1C=C(C#N)C=CC=1C(=O)N1CC2(C1)CC(C2)N(C=1C2=C(N=CN=1)NC=C2)C JFZIQIRABHLLKM-UHFFFAOYSA-N 0.000 claims description 2
- RSVWDCQCHSMMND-UHFFFAOYSA-N 3-fluoro-5-[6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptane-2-carbonyl]benzonitrile Chemical compound FC=1C=C(C#N)C=C(C=1)C(=O)N1CC2(C1)CC(C2)N(C=1C2=C(N=CN=1)NC=C2)C RSVWDCQCHSMMND-UHFFFAOYSA-N 0.000 claims description 2
- BLZMXOQDHLRLNE-UHFFFAOYSA-N 4-[2-[6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptan-2-yl]-2-oxoethyl]benzonitrile Chemical compound CN(C1CC2(CN(C2)C(CC2=CC=C(C#N)C=C2)=O)C1)C=1C2=C(N=CN=1)NC=C2 BLZMXOQDHLRLNE-UHFFFAOYSA-N 0.000 claims description 2
- YVQCNTJXPDBBFP-UHFFFAOYSA-N 4-[2-[9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3-azaspiro[5.5]undecan-3-yl]-2-oxoethoxy]benzonitrile Chemical compound CN(C1CCC2(CCN(CC2)C(COC2=CC=C(C#N)C=C2)=O)CC1)C=1C2=C(N=CN=1)NC=C2 YVQCNTJXPDBBFP-UHFFFAOYSA-N 0.000 claims description 2
- VHLCOTQBKUEWMM-UHFFFAOYSA-N 4-[2-[9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3-azaspiro[5.5]undecan-3-yl]-2-oxoethyl]benzonitrile Chemical compound CN(C1CCC2(CCN(CC2)C(CC2=CC=C(C#N)C=C2)=O)CC1)C=1C2=C(N=CN=1)NC=C2 VHLCOTQBKUEWMM-UHFFFAOYSA-N 0.000 claims description 2
- DICQZGXPVOZSBT-UHFFFAOYSA-N 4-[6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptan-2-yl]-4-oxobutanenitrile Chemical compound CN(C1CC2(CN(C2)C(CCC#N)=O)C1)C=1C2=C(N=CN=1)NC=C2 DICQZGXPVOZSBT-UHFFFAOYSA-N 0.000 claims description 2
- JMMCTEYNTCZHTP-UHFFFAOYSA-N 4-[6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptane-2-carbonyl]benzenesulfonamide Chemical compound CN(C1CC2(CN(C2)C(=O)C2=CC=C(C=C2)S(=O)(=O)N)C1)C=1C2=C(N=CN=1)NC=C2 JMMCTEYNTCZHTP-UHFFFAOYSA-N 0.000 claims description 2
- OKEQLCCGZRYWNG-UHFFFAOYSA-N 4-[6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptane-2-carbonyl]cyclohexan-1-one Chemical compound CN(C1CC2(CN(C2)C(=O)C2CCC(CC2)=O)C1)C=1C2=C(N=CN=1)NC=C2 OKEQLCCGZRYWNG-UHFFFAOYSA-N 0.000 claims description 2
- OVXAMKJPGRRMNP-UHFFFAOYSA-N 4-[9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3-azaspiro[5.5]undecan-3-yl]-4-oxobutanenitrile Chemical compound CN(C1CCC2(CCN(CC2)C(CCC#N)=O)CC1)C=1C2=C(N=CN=1)NC=C2 OVXAMKJPGRRMNP-UHFFFAOYSA-N 0.000 claims description 2
- OPARRXAAPGSVPZ-UHFFFAOYSA-N 4-[9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3-azaspiro[5.5]undecane-3-carbonyl]benzenesulfonamide Chemical compound CN(C1CCC2(CCN(CC2)C(=O)C2=CC=C(C=C2)S(=O)(=O)N)CC1)C=1C2=C(N=CN=1)NC=C2 OPARRXAAPGSVPZ-UHFFFAOYSA-N 0.000 claims description 2
- WTPATCQZIMFXCI-UHFFFAOYSA-N 4-[9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3-azaspiro[5.5]undecane-3-carbonyl]cyclohexan-1-one Chemical compound CN(C1CCC2(CCN(CC2)C(=O)C2CCC(CC2)=O)CC1)C=1C2=C(N=CN=1)NC=C2 WTPATCQZIMFXCI-UHFFFAOYSA-N 0.000 claims description 2
- NVLGXEIBUWQQQX-UHFFFAOYSA-N 5-[6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptane-2-carbonyl]pyridine-2-carbonitrile Chemical compound CN(C1CC2(CN(C2)C(=O)C=2C=CC(=NC=2)C#N)C1)C=1C2=C(N=CN=1)NC=C2 NVLGXEIBUWQQQX-UHFFFAOYSA-N 0.000 claims description 2
- GORVKYKEYCQOMR-UHFFFAOYSA-N 5-fluoro-2-methyl-4-[6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptane-2-carbonyl]benzonitrile Chemical compound FC=1C(=CC(=C(C#N)C=1)C)C(=O)N1CC2(C1)CC(C2)N(C=1C2=C(N=CN=1)NC=C2)C GORVKYKEYCQOMR-UHFFFAOYSA-N 0.000 claims description 2
- OYCCDIZFYCFPGP-UHFFFAOYSA-N 9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-N-(2,2,2-trifluoroethyl)-3-azaspiro[5.5]undecane-3-carboxamide Chemical compound CN(C1CCC2(CCN(CC2)C(=O)NCC(F)(F)F)CC1)C=1C2=C(N=CN=1)NC=C2 OYCCDIZFYCFPGP-UHFFFAOYSA-N 0.000 claims description 2
- KEBCLGFCDNZXSO-UHFFFAOYSA-N 9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-N-(5-methyl-1,3-thiazol-2-yl)-3-azaspiro[5.5]undecane-3-carboxamide Chemical compound CN(C1CCC2(CCN(CC2)C(=O)NC=2SC(=CN=2)C)CC1)C=1C2=C(N=CN=1)NC=C2 KEBCLGFCDNZXSO-UHFFFAOYSA-N 0.000 claims description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
- HMDHLDHOSIRUNH-UHFFFAOYSA-N N,N-diethyl-9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3-azaspiro[5.5]undecane-3-sulfonamide Chemical compound C(C)N(S(=O)(=O)N1CCC2(CC1)CCC(CC2)N(C=1C2=C(N=CN=1)NC=C2)C)CC HMDHLDHOSIRUNH-UHFFFAOYSA-N 0.000 claims description 2
- WDAYNCDLBOQLBM-UHFFFAOYSA-N N-(1-methylpyrazol-3-yl)-9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3-azaspiro[5.5]undecane-3-carboxamide Chemical compound CN(C1CCC2(CCN(CC2)C(=O)NC2=NN(C=C2)C)CC1)C=1C2=C(N=CN=1)NC=C2 WDAYNCDLBOQLBM-UHFFFAOYSA-N 0.000 claims description 2
- RCSIOFWAUFWXMM-UHFFFAOYSA-N N-(2-ethylsulfonyl-2-azaspiro[3.3]heptan-6-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C(C)S(=O)(=O)N1CC2(C1)CC(C2)N(C=1C2=C(N=CN=1)NC=C2)C RCSIOFWAUFWXMM-UHFFFAOYSA-N 0.000 claims description 2
- QUCHLKDPDCZYBN-UHFFFAOYSA-N N-(3-chlorophenyl)-6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptane-2-carboxamide Chemical compound ClC=1C=C(C=CC=1)NC(=O)N1CC2(C1)CC(C2)N(C=1C2=C(N=CN=1)NC=C2)C QUCHLKDPDCZYBN-UHFFFAOYSA-N 0.000 claims description 2
- WYWWHIQQIUMFIF-UHFFFAOYSA-N N-(3-methoxy-1,2,4-thiadiazol-5-yl)-6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptane-2-carboxamide Chemical compound COC1=NSC(NC(=O)N2CC3(CC(C3)N(C)C3=NC=NC4=C3C=CN4)C2)=N1 WYWWHIQQIUMFIF-UHFFFAOYSA-N 0.000 claims description 2
- NKUQNCLCIQSSRV-UHFFFAOYSA-N N-(4-methoxyphenyl)-9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3-azaspiro[5.5]undecane-3-carboxamide Chemical compound COC1=CC=C(C=C1)NC(=O)N1CCC2(CC1)CCC(CC2)N(C=1C2=C(N=CN=1)NC=C2)C NKUQNCLCIQSSRV-UHFFFAOYSA-N 0.000 claims description 2
- LXOKAPQCXPKDTG-UHFFFAOYSA-N N-(5-chloro-1,3-thiazol-2-yl)-9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3-azaspiro[5.5]undecane-3-carboxamide Chemical compound ClC1=CN=C(S1)NC(=O)N1CCC2(CC1)CCC(CC2)N(C=1C2=C(N=CN=1)NC=C2)C LXOKAPQCXPKDTG-UHFFFAOYSA-N 0.000 claims description 2
- DQQOODQSRPYKBY-UHFFFAOYSA-N N-(5-cyano-1,3-thiazol-2-yl)-9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3-azaspiro[5.5]undecane-3-carboxamide Chemical compound C(#N)C1=CN=C(S1)NC(=O)N1CCC2(CC1)CCC(CC2)N(C=1C2=C(N=CN=1)NC=C2)C DQQOODQSRPYKBY-UHFFFAOYSA-N 0.000 claims description 2
- BYGYNEAFWJJNLV-UHFFFAOYSA-N N-(5-cyanopyridin-2-yl)-9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3-azaspiro[5.5]undecane-3-carboxamide Chemical compound C(#N)C=1C=CC(=NC=1)NC(=O)N1CCC2(CC1)CCC(CC2)N(C=1C2=C(N=CN=1)NC=C2)C BYGYNEAFWJJNLV-UHFFFAOYSA-N 0.000 claims description 2
- IDHQIVCHWLXHEJ-UHFFFAOYSA-N N-(5-fluoro-1,3-thiazol-2-yl)-9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3-azaspiro[5.5]undecane-3-carboxamide Chemical compound FC1=CN=C(S1)NC(=O)N1CCC2(CC1)CCC(CC2)N(C=1C2=C(N=CN=1)NC=C2)C IDHQIVCHWLXHEJ-UHFFFAOYSA-N 0.000 claims description 2
- PSCQQIWXFNPLPN-UHFFFAOYSA-N N-(5-methylpyrazin-2-yl)-9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3-azaspiro[5.5]undecane-3-carboxamide Chemical compound CN(C1CCC2(CCN(CC2)C(=O)NC2=NC=C(N=C2)C)CC1)C=1C2=C(N=CN=1)NC=C2 PSCQQIWXFNPLPN-UHFFFAOYSA-N 0.000 claims description 2
- SBJVNDZLFROZPP-UHFFFAOYSA-N N-(6-methoxypyridin-2-yl)-9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3-azaspiro[5.5]undecane-3-carboxamide Chemical compound COC1=CC=CC(=N1)NC(=O)N1CCC2(CC1)CCC(CC2)N(C=1C2=C(N=CN=1)NC=C2)C SBJVNDZLFROZPP-UHFFFAOYSA-N 0.000 claims description 2
- FGFBDNHPJMDHEB-UHFFFAOYSA-N N-methyl-9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3-azaspiro[5.5]undecane-3-carboxamide Chemical compound CNC(=O)N1CCC2(CC1)CCC(CC2)N(C=1C2=C(N=CN=1)NC=C2)C FGFBDNHPJMDHEB-UHFFFAOYSA-N 0.000 claims description 2
- OAGRNNXYMBQBJM-UHFFFAOYSA-N N-methyl-N-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-3-(2,2,2-trifluoroethyl)-3-azaspiro[5.5]undecan-9-amine Chemical compound CN(C1CCC2(CCN(CC2)CC(F)(F)F)CC1)C=1C2=C(N=CN=1)NC=C2 OAGRNNXYMBQBJM-UHFFFAOYSA-N 0.000 claims description 2
- VSJTWTYUUIQHJS-UHFFFAOYSA-N N-methyl-N-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-3-(2,2,2-trifluoroethylsulfonyl)-3-azaspiro[5.5]undecan-9-amine Chemical compound CN(C1CCC2(CC1)CCN(CC2)S(=O)(=O)CC(F)(F)F)c1ncnc2[nH]ccc12 VSJTWTYUUIQHJS-UHFFFAOYSA-N 0.000 claims description 2
- JXRUFSJHYPIPGT-UHFFFAOYSA-N [4-(1-methylpyrazol-3-yl)phenyl]-[6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptan-2-yl]methanone Chemical compound CN1N=C(C=C1)C1=CC=C(C=C1)C(=O)N1CC2(C1)CC(C2)N(C=1C2=C(N=CN=1)NC=C2)C JXRUFSJHYPIPGT-UHFFFAOYSA-N 0.000 claims description 2
- NIZTVNTVGIDDME-UHFFFAOYSA-N [6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptan-2-yl]-(3-methylthiophen-2-yl)methanone Chemical compound CN(C1CC2(CN(C2)C(=O)C=2SC=CC=2C)C1)C=1C2=C(N=CN=1)NC=C2 NIZTVNTVGIDDME-UHFFFAOYSA-N 0.000 claims description 2
- FAISIFWMTUYCRH-UHFFFAOYSA-N [6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptan-2-yl]-(4-prop-1-ynylphenyl)methanone Chemical compound CN(C1CC2(CN(C2)C(=O)C2=CC=C(C=C2)C#CC)C1)C=1C2=C(N=CN=1)NC=C2 FAISIFWMTUYCRH-UHFFFAOYSA-N 0.000 claims description 2
- SMTKSVOBZNXDDB-UHFFFAOYSA-N [6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptan-2-yl]-[4-(trifluoromethyl)phenyl]methanone Chemical compound CN(C1CC2(CN(C2)C(=O)C2=CC=C(C=C2)C(F)(F)F)C1)C=1C2=C(N=CN=1)NC=C2 SMTKSVOBZNXDDB-UHFFFAOYSA-N 0.000 claims description 2
- UYTMDBJEBPZRMH-UHFFFAOYSA-N [9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3-azaspiro[5.5]undecan-3-yl]-(3-methylthiophen-2-yl)methanone Chemical compound CN(C1CCC2(CCN(CC2)C(=O)C=2SC=CC=2C)CC1)C=1C2=C(N=CN=1)NC=C2 UYTMDBJEBPZRMH-UHFFFAOYSA-N 0.000 claims description 2
- VOOLOUSQTDSPMN-UHFFFAOYSA-N [9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3-azaspiro[5.5]undecan-3-yl]-[3-(trifluoromethoxy)phenyl]methanone Chemical compound CN(C1CCC2(CCN(CC2)C(=O)C2=CC(=CC=C2)OC(F)(F)F)CC1)C=1C2=C(N=CN=1)NC=C2 VOOLOUSQTDSPMN-UHFFFAOYSA-N 0.000 claims description 2
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims description 2
- 239000000739 antihistaminic agent Substances 0.000 claims description 2
- 229940125715 antihistaminic agent Drugs 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 229940046731 calcineurin inhibitors Drugs 0.000 claims description 2
- CCGKOQOJPYTBIH-UHFFFAOYSA-N ethenone Chemical compound C=C=O CCGKOQOJPYTBIH-UHFFFAOYSA-N 0.000 claims description 2
- FJMRXECXSJRKNH-UHFFFAOYSA-N ethyl 6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptane-2-carboxylate Chemical compound CN(C1CC2(CN(C2)C(=O)OCC)C1)C=1C2=C(N=CN=1)NC=C2 FJMRXECXSJRKNH-UHFFFAOYSA-N 0.000 claims description 2
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims description 2
- 229960000681 leflunomide Drugs 0.000 claims description 2
- 229960000485 methotrexate Drugs 0.000 claims description 2
- RYWURBBROSNSBL-UHFFFAOYSA-N methyl 6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptane-2-carboxylate Chemical compound CN(C1CC2(CN(C2)C(=O)OC)C1)C=1C2=C(N=CN=1)NC=C2 RYWURBBROSNSBL-UHFFFAOYSA-N 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- RJABSAMGJTXIEB-UHFFFAOYSA-N propan-2-yl 9-[6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl(methyl)amino]-3-azaspiro[5.5]undecane-3-carboxylate Chemical compound C(C)(C)OC(=O)N1CCC2(CC1)CCC(CC2)N(C)C=1C2=C(N=CN=1)NCC2 RJABSAMGJTXIEB-UHFFFAOYSA-N 0.000 claims description 2
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 claims description 2
- MWFZEGBBWGJGPE-UHFFFAOYSA-N N-(5-methoxypyrazin-2-yl)-9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3-azaspiro[5.5]undecane-3-carboxamide Chemical compound COC=1N=CC(=NC=1)NC(=O)N1CCC2(CC1)CCC(CC2)N(C=1C2=C(N=CN=1)NC=C2)C MWFZEGBBWGJGPE-UHFFFAOYSA-N 0.000 claims 2
- ONWHHMSVGORGKS-UHFFFAOYSA-N (4-chlorophenyl)-[6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptan-2-yl]methanone Chemical compound ClC1=CC=C(C=C1)C(=O)N1CC2(C1)CC(C2)N(C=1C2=C(N=CN=1)NC=C2)C ONWHHMSVGORGKS-UHFFFAOYSA-N 0.000 claims 1
- DNHULVKSPPFKBI-UHFFFAOYSA-N (6-methylpyrazin-2-yl)-[9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3-azaspiro[5.5]undecan-3-yl]methanone Chemical compound CC1=CN=CC(=N1)C(=O)N1CCC2(CC1)CCC(CC2)N(C=1C2=C(N=CN=1)NC=C2)C DNHULVKSPPFKBI-UHFFFAOYSA-N 0.000 claims 1
- KWVQZNXGJOENFF-UHFFFAOYSA-N 1-[6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptan-2-yl]ethanone Chemical compound CN(C1CC2(C1)CN(C2)C(C)=O)C1=NC=NC2=C1C=CN2 KWVQZNXGJOENFF-UHFFFAOYSA-N 0.000 claims 1
- CHVVGJSZHFREBZ-UHFFFAOYSA-N 1-benzothiophen-2-yl-[9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3-azaspiro[5.5]undecan-3-yl]methanone Chemical compound S1C2=C(C=C1C(=O)N1CCC3(CC1)CCC(CC3)N(C=1C3=C(N=CN=1)NC=C3)C)C=CC=C2 CHVVGJSZHFREBZ-UHFFFAOYSA-N 0.000 claims 1
- NLTNWHIVTSQFOR-UHFFFAOYSA-N 3-methyl-4-[6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptane-2-carbonyl]benzonitrile Chemical compound CC=1C=C(C#N)C=CC=1C(=O)N1CC2(C1)CC(C2)N(C=1C2=C(N=CN=1)NC=C2)C NLTNWHIVTSQFOR-UHFFFAOYSA-N 0.000 claims 1
- GEDPIBRYKFZQSE-UHFFFAOYSA-N 4,4,4-trifluoro-1-[6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptan-2-yl]butan-1-one Chemical compound FC(CCC(=O)N1CC2(C1)CC(C2)N(C=1C2=C(N=CN=1)NC=C2)C)(F)F GEDPIBRYKFZQSE-UHFFFAOYSA-N 0.000 claims 1
- JWADAFWPIRUEAE-UHFFFAOYSA-N 4,4,4-trifluoro-1-[9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3-azaspiro[5.5]undecan-3-yl]butan-1-one Chemical compound FC(CCC(=O)N1CCC2(CC1)CCC(CC2)N(C=1C2=C(N=CN=1)NC=C2)C)(F)F JWADAFWPIRUEAE-UHFFFAOYSA-N 0.000 claims 1
- DCVLNAFSEGHRSD-UHFFFAOYSA-N N-(4-cyanophenyl)-9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3-azaspiro[5.5]undecane-3-carboxamide Chemical compound C(#N)C1=CC=C(C=C1)NC(=O)N1CCC2(CC1)CCC(CC2)N(C=1C2=C(N=CN=1)NC=C2)C DCVLNAFSEGHRSD-UHFFFAOYSA-N 0.000 claims 1
- MYRNMXFQKTVTMG-UHFFFAOYSA-N N-(6-cyanopyridin-2-yl)-9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3-azaspiro[5.5]undecane-3-carboxamide Chemical compound C(#N)C1=CC=CC(=N1)NC(=O)N1CCC2(CC1)CCC(CC2)N(C=1C2=C(N=CN=1)NC=C2)C MYRNMXFQKTVTMG-UHFFFAOYSA-N 0.000 claims 1
- BPJQBRJZQOSXFY-UHFFFAOYSA-N [6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptan-2-yl]-[3-(trifluoromethoxy)phenyl]methanone Chemical compound CN(C1CC2(CN(C2)C(=O)C2=CC(=CC=C2)OC(F)(F)F)C1)C=1C2=C(N=CN=1)NC=C2 BPJQBRJZQOSXFY-UHFFFAOYSA-N 0.000 claims 1
- BTFPCGNUKIYHMY-UHFFFAOYSA-N [6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptan-2-yl]-[3-(trifluoromethyl)phenyl]methanone Chemical compound CN(C1CC2(CN(C2)C(=O)C2=CC(=CC=C2)C(F)(F)F)C1)C=1C2=C(N=CN=1)NC=C2 BTFPCGNUKIYHMY-UHFFFAOYSA-N 0.000 claims 1
- XZLVYKRCLBOZJX-UHFFFAOYSA-N [6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptan-2-yl]-pyrazin-2-ylmethanone Chemical compound CN(C1CC2(CN(C2)C(=O)C2=NC=CN=C2)C1)C=1C2=C(N=CN=1)NC=C2 XZLVYKRCLBOZJX-UHFFFAOYSA-N 0.000 claims 1
- CMFLIQCZDGOBDD-UHFFFAOYSA-N [9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3-azaspiro[5.5]undecan-3-yl]-pyridin-3-ylmethanone Chemical compound CN(C1CCC2(CCN(CC2)C(=O)C=2C=NC=CC=2)CC1)C=1C2=C(N=CN=1)NC=C2 CMFLIQCZDGOBDD-UHFFFAOYSA-N 0.000 claims 1
- YEZAOBNAIMPGAB-UHFFFAOYSA-N cyclopropyl-[9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3-azaspiro[5.5]undecan-3-yl]methanone Chemical compound C1(CC1)C(=O)N1CCC2(CC1)CCC(CC2)N(C=1C2=C(N=CN=1)NC=C2)C YEZAOBNAIMPGAB-UHFFFAOYSA-N 0.000 claims 1
- IEZLVROUSQUEJE-UHFFFAOYSA-N ethyl 9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3-azaspiro[5.5]undecane-3-carboxylate Chemical compound C(C)OC(=O)N1CCC2(CC1)CCC(CC2)N(C=1C2=C(N=CN=1)NC=C2)C IEZLVROUSQUEJE-UHFFFAOYSA-N 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 29
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 26
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 23
- 239000011541 reaction mixture Substances 0.000 description 21
- 238000000034 method Methods 0.000 description 20
- 108010000837 Janus Kinase 1 Proteins 0.000 description 19
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 19
- 230000005764 inhibitory process Effects 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 16
- 102000006503 Janus Kinase 2 Human genes 0.000 description 15
- 108010019437 Janus Kinase 2 Proteins 0.000 description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000003556 assay Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 125000001153 fluoro group Chemical group F* 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 239000000758 substrate Substances 0.000 description 12
- 235000019000 fluorine Nutrition 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- XVJLCYMKPXERHP-UHFFFAOYSA-N CNC1CCC2(CCN(CC2)C(=O)OC(C)(C)C)CC1 Chemical compound CNC1CCC2(CCN(CC2)C(=O)OC(C)(C)C)CC1 XVJLCYMKPXERHP-UHFFFAOYSA-N 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 108010019421 Janus Kinase 3 Proteins 0.000 description 8
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 8
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 102000015617 Janus Kinases Human genes 0.000 description 7
- 108010024121 Janus Kinases Proteins 0.000 description 7
- 238000001819 mass spectrum Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 description 6
- 108010010057 TYK2 Kinase Proteins 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 125000004429 atom Chemical group 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 235000019439 ethyl acetate Nutrition 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 238000004809 thin layer chromatography Methods 0.000 description 5
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 239000007995 HEPES buffer Substances 0.000 description 4
- 102000042838 JAK family Human genes 0.000 description 4
- 108091082332 JAK family Proteins 0.000 description 4
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 4
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 229920004890 Triton X-100 Polymers 0.000 description 4
- 239000013504 Triton X-100 Substances 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 125000004414 alkyl thio group Chemical group 0.000 description 4
- 239000012131 assay buffer Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- OJCCUUWVUOCZAA-UHFFFAOYSA-N 3-methoxy-1,2,4-thiadiazol-5-amine Chemical compound COC1=NSC(N)=N1 OJCCUUWVUOCZAA-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 238000007429 general method Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 3
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 2
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 230000004163 JAK-STAT signaling pathway Effects 0.000 description 2
- 229940116839 Janus kinase 1 inhibitor Drugs 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 102000003675 cytokine receptors Human genes 0.000 description 2
- 108010057085 cytokine receptors Proteins 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 125000003709 fluoroalkyl group Chemical group 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 231100000590 oncogenic Toxicity 0.000 description 2
- 230000002246 oncogenic effect Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000012746 preparative thin layer chromatography Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- ANFHSFUVNIOWRN-UHFFFAOYSA-N 1-[9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3-azaspiro[5.5]undecan-3-yl]-2-phenoxyethanone Chemical compound CN(C1CCC2(CC1)CCN(CC2)C(=O)COC1=CC=CC=C1)C1=NC=NC2=C1C=CN2 ANFHSFUVNIOWRN-UHFFFAOYSA-N 0.000 description 1
- QKCIVLFBPUAUSP-UHFFFAOYSA-N 2,6-difluoro-3-[6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptane-2-carbonyl]benzonitrile Chemical compound FC1=C(C#N)C(=CC=C1C(=O)N1CC2(C1)CC(C2)N(C=1C2=C(N=CN=1)NC=C2)C)F QKCIVLFBPUAUSP-UHFFFAOYSA-N 0.000 description 1
- PQGAOWILIFAGPY-UHFFFAOYSA-N 2-hydroxy-1-[9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3-azaspiro[5.5]undecan-3-yl]ethanone Chemical compound OCC(=O)N1CCC2(CC1)CCC(CC2)N(C=1C2=C(N=CN=1)NC=C2)C PQGAOWILIFAGPY-UHFFFAOYSA-N 0.000 description 1
- GCGUBZBZLXJHDS-UHFFFAOYSA-N 3-[9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3-azaspiro[5.5]undecan-3-yl]-3-oxopropane-1-sulfonamide Chemical compound CN(C1CCC2(CCN(CC2)C(CCS(=O)(=O)N)=O)CC1)C=1C2=C(N=CN=1)NC=C2 GCGUBZBZLXJHDS-UHFFFAOYSA-N 0.000 description 1
- ZFWSKEVFMFBFBQ-UHFFFAOYSA-N 3-[9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3-azaspiro[5.5]undecan-3-yl]-3-oxopropanenitrile Chemical compound CN(C1CCC2(CCN(CC2)C(CC#N)=O)CC1)C=1C2=C(N=CN=1)NC=C2 ZFWSKEVFMFBFBQ-UHFFFAOYSA-N 0.000 description 1
- NGZFAOTZJSIETF-UHFFFAOYSA-N 3-fluoro-5-[2-[9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3-azaspiro[5.5]undecan-3-yl]-2-oxoethoxy]benzonitrile Chemical compound FC=1C=C(C#N)C=C(C=1)OCC(=O)N1CCC2(CC1)CCC(CC2)N(C=1C2=C(N=CN=1)NC=C2)C NGZFAOTZJSIETF-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- BPTCCCTWWAUJRK-UHFFFAOYSA-N 4-chloro-7h-pyrrolo[2,3-d]pyrimidine Chemical compound ClC1=NC=NC2=C1C=CN2 BPTCCCTWWAUJRK-UHFFFAOYSA-N 0.000 description 1
- ZWKNDLMYSLLMRF-UHFFFAOYSA-N 4-cyano-3-fluorobenzoic acid Chemical compound OC(=O)C1=CC=C(C#N)C(F)=C1 ZWKNDLMYSLLMRF-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- TZZCOSKZMZQKRT-UHFFFAOYSA-N 9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-N-(1,3-thiazol-2-yl)-3-azaspiro[5.5]undecane-3-carboxamide Chemical compound CN(C1CCC2(CCN(CC2)C(=O)NC=2SC=CN=2)CC1)C=1C2=C(N=CN=1)NC=C2 TZZCOSKZMZQKRT-UHFFFAOYSA-N 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- RNBAIEJDOGSDBC-UHFFFAOYSA-N CNC1CC2(C1)CN(C2)C(=O)OC(C)(C)C Chemical compound CNC1CC2(C1)CN(C2)C(=O)OC(C)(C)C RNBAIEJDOGSDBC-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241001125671 Eretmochelys imbricata Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000010787 Interleukin-4 Receptors Human genes 0.000 description 1
- 108010038486 Interleukin-4 Receptors Proteins 0.000 description 1
- 102100026244 Interleukin-9 receptor Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CAFIZRGZPMAVOD-UHFFFAOYSA-N N-(2-azaspiro[3.3]heptan-6-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)C1CC2(CNC2)C1 CAFIZRGZPMAVOD-UHFFFAOYSA-N 0.000 description 1
- WXXYIUCRGXQTIQ-UHFFFAOYSA-N N-(3-methoxyphenyl)-9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3-azaspiro[5.5]undecane-3-carboxamide Chemical compound COC=1C=C(C=CC=1)NC(=O)N1CCC2(CC1)CCC(CC2)N(C=1C2=C(N=CN=1)NC=C2)C WXXYIUCRGXQTIQ-UHFFFAOYSA-N 0.000 description 1
- HALYKECWLOUIFT-UHFFFAOYSA-N N-(5-methoxypyridin-2-yl)-9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3-azaspiro[5.5]undecane-3-carboxamide Chemical compound COC=1C=CC(=NC=1)NC(=O)N1CCC2(CC1)CCC(CC2)N(C=1C2=C(N=CN=1)NC=C2)C HALYKECWLOUIFT-UHFFFAOYSA-N 0.000 description 1
- LBGAWZULJFMLJK-UHFFFAOYSA-N N-(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-methyl-3-propylsulfonyl-3-azaspiro[5.5]undecan-9-amine Chemical compound N1=CN=C(C2=C1NCC2)N(C1CCC2(CCN(CC2)S(=O)(=O)CCC)CC1)C LBGAWZULJFMLJK-UHFFFAOYSA-N 0.000 description 1
- DCMMXGZUFQEARI-UHFFFAOYSA-N N-methyl-N-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-3-azaspiro[5.5]undecan-9-amine 2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CN(C1CCC2(CCNCC2)CC1)c1ncnc2[nH]ccc12 DCMMXGZUFQEARI-UHFFFAOYSA-N 0.000 description 1
- 108010029477 STAT5 Transcription Factor Proteins 0.000 description 1
- 102100024481 Signal transducer and activator of transcription 5A Human genes 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- MMWDDCAGLRZJJA-UHFFFAOYSA-N [6-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-2-azaspiro[3.3]heptan-2-yl]-(1H-pyrazol-5-yl)methanone Chemical compound CN(C1CC2(CN(C2)C(=O)C2=NNC=C2)C1)C=1C2=C(N=CN=1)NC=C2 MMWDDCAGLRZJJA-UHFFFAOYSA-N 0.000 description 1
- ZYENMGDWIPPETF-UHFFFAOYSA-N [9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3-azaspiro[5.5]undecan-3-yl]-[3-(trifluoromethyl)phenyl]methanone Chemical compound CN(C1CCC2(CCN(CC2)C(=O)C2=CC(=CC=C2)C(F)(F)F)CC1)C=1C2=C(N=CN=1)NC=C2 ZYENMGDWIPPETF-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 125000005018 aryl alkenyl group Chemical group 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000005015 aryl alkynyl group Chemical group 0.000 description 1
- 125000004350 aryl cycloalkyl group Chemical group 0.000 description 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- PCDHSSHKDZYLLI-UHFFFAOYSA-N butan-1-one Chemical compound CCC[C]=O PCDHSSHKDZYLLI-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000005357 cycloalkylalkynyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 125000005959 diazepanyl group Chemical group 0.000 description 1
- 125000004639 dihydroindenyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 125000004404 heteroalkyl group Chemical group 0.000 description 1
- 125000004447 heteroarylalkenyl group Chemical group 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- 125000005312 heteroarylalkynyl group Chemical group 0.000 description 1
- 125000005349 heteroarylcycloalkyl group Chemical group 0.000 description 1
- 125000005326 heteroaryloxy alkyl group Chemical group 0.000 description 1
- 125000004449 heterocyclylalkenyl group Chemical group 0.000 description 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 108040003607 interleukin-13 receptor activity proteins Proteins 0.000 description 1
- 108040002039 interleukin-15 receptor activity proteins Proteins 0.000 description 1
- 102000008616 interleukin-15 receptor activity proteins Human genes 0.000 description 1
- 108040002099 interleukin-21 receptor activity proteins Proteins 0.000 description 1
- 102000008640 interleukin-21 receptor activity proteins Human genes 0.000 description 1
- 108040006852 interleukin-4 receptor activity proteins Proteins 0.000 description 1
- 108040006861 interleukin-7 receptor activity proteins Proteins 0.000 description 1
- 108040006862 interleukin-9 receptor activity proteins Proteins 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 238000002514 liquid chromatography mass spectrum Methods 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 1
- DKQGJUUUWQUJER-UHFFFAOYSA-N methyl 9-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3-azaspiro[5.5]undecane-3-carboxylate Chemical compound CN(C1CCC2(CCN(CC2)C(=O)OC)CC1)C=1C2=C(N=CN=1)NC=C2 DKQGJUUUWQUJER-UHFFFAOYSA-N 0.000 description 1
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- XAMUDJHXFNRLCY-UHFFFAOYSA-N phenthoate Chemical compound CCOC(=O)C(SP(=S)(OC)OC)C1=CC=CC=C1 XAMUDJHXFNRLCY-UHFFFAOYSA-N 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 150000004944 pyrrolopyrimidines Chemical class 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 150000003461 sulfonyl halides Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- HQHRAGXKFOTSQE-UHFFFAOYSA-N tert-butyl 6-oxo-2-azaspiro[3.3]heptane-2-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC21CC(=O)C2 HQHRAGXKFOTSQE-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000006407 thiazinanyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862646167P | 2018-03-21 | 2018-03-21 | |
| US62/646,167 | 2018-03-21 | ||
| PCT/US2019/022657 WO2019182924A1 (en) | 2018-03-21 | 2019-03-18 | Jak inhibitors |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021518379A JP2021518379A (ja) | 2021-08-02 |
| JPWO2019182924A5 JPWO2019182924A5 (https=) | 2022-03-30 |
| JP2021518379A5 JP2021518379A5 (https=) | 2022-03-30 |
| JP7462951B2 true JP7462951B2 (ja) | 2024-04-08 |
Family
ID=67986579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020550114A Active JP7462951B2 (ja) | 2018-03-21 | 2019-03-18 | Ｊａｋ阻害剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11365188B2 (https=) |
| EP (1) | EP3768272B1 (https=) |
| JP (1) | JP7462951B2 (https=) |
| CN (1) | CN111936144B (https=) |
| AU (1) | AU2019237991B2 (https=) |
| CA (1) | CA3093706A1 (https=) |
| WO (1) | WO2019182924A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA202092441A1 (ru) | 2016-06-07 | 2021-05-21 | Джакобио Фармасьютикалс Ко., Лтд. | Новые гетероциклические производные, применимые в качестве ингибиторов shp2 |
| KR20240026521A (ko) | 2017-03-23 | 2024-02-28 | 자코바이오 파마슈티칼스 컴퍼니 리미티드 | Shp2 억제제로서 유용한 신규한 헤테로환형 유도체 |
| CN112839935A (zh) | 2018-09-26 | 2021-05-25 | 北京加科思新药研发有限公司 | 可用作shp2抑制剂的新型杂环衍生物 |
| JP2022506682A (ja) * | 2018-11-05 | 2022-01-17 | アビスタ ファーマ ソリューションズ，インコーポレーテッド | 化合物 |
| CA3125039A1 (en) | 2019-01-23 | 2020-07-30 | Theravance Biopharma R&D Ip, Llc | Imidazo[1,5-a]pyridine, 1,2,4-triazolo[4,3-a]pyridine and imidazo[1,5-a]pyrazine as jak inhibitors |
| WO2020155931A1 (zh) | 2019-01-30 | 2020-08-06 | 格格巫（珠海）生物科技有限公司 | 一种jak抑制剂及其制备方法 |
| WO2022117075A1 (zh) * | 2020-12-04 | 2022-06-09 | 广州费米子科技有限责任公司 | 氮杂并环化合物、其制备方法及其用途 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015500845A (ja) | 2011-12-21 | 2015-01-08 | ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． | ピロール−６員ヘテロアリール環誘導体、その合成法およびその医薬用途 |
| JP2016539137A (ja) | 2013-12-05 | 2016-12-15 | ファイザー・インク | ピロロ［２，３−ｄ］ピリミジニル、ピロロ［２，３−ｂ］ピラジニル、およびピロロ［２，３−ｄ］ピリジニルアクリルアミド |
| JP2017506675A (ja) | 2014-02-28 | 2017-03-09 | ニンバス ラクシュミ， インコーポレイテッド | Ｔｙｋ２阻害剤およびその使用 |
| JP2018502899A (ja) | 2015-01-20 | 2018-02-01 | 无▲錫▼福祈制▲薬▼有限公司Ｗｕｘｉ Ｆｏｒｔｕｎｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．，Ｌｔｄ | Ｊａｋ阻害剤 |
| WO2018169700A1 (en) | 2017-03-14 | 2018-09-20 | Sunshine Lake Pharma Co., Ltd. | Substituted heteroaryl compounds and methods of use |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3180344B1 (en) * | 2014-08-12 | 2019-09-18 | Pfizer Inc | Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase |
-
2019
- 2019-03-18 JP JP2020550114A patent/JP7462951B2/ja active Active
- 2019-03-18 CA CA3093706A patent/CA3093706A1/en active Pending
- 2019-03-18 US US16/979,455 patent/US11365188B2/en active Active
- 2019-03-18 AU AU2019237991A patent/AU2019237991B2/en active Active
- 2019-03-18 WO PCT/US2019/022657 patent/WO2019182924A1/en not_active Ceased
- 2019-03-18 EP EP19770607.0A patent/EP3768272B1/en active Active
- 2019-03-18 CN CN201980020463.5A patent/CN111936144B/zh active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015500845A (ja) | 2011-12-21 | 2015-01-08 | ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． | ピロール−６員ヘテロアリール環誘導体、その合成法およびその医薬用途 |
| JP2016539137A (ja) | 2013-12-05 | 2016-12-15 | ファイザー・インク | ピロロ［２，３−ｄ］ピリミジニル、ピロロ［２，３−ｂ］ピラジニル、およびピロロ［２，３−ｄ］ピリジニルアクリルアミド |
| JP2017506675A (ja) | 2014-02-28 | 2017-03-09 | ニンバス ラクシュミ， インコーポレイテッド | Ｔｙｋ２阻害剤およびその使用 |
| JP2018502899A (ja) | 2015-01-20 | 2018-02-01 | 无▲錫▼福祈制▲薬▼有限公司Ｗｕｘｉ Ｆｏｒｔｕｎｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．，Ｌｔｄ | Ｊａｋ阻害剤 |
| WO2018169700A1 (en) | 2017-03-14 | 2018-09-20 | Sunshine Lake Pharma Co., Ltd. | Substituted heteroaryl compounds and methods of use |
Non-Patent Citations (2)
| Title |
|---|
| C.G.WERMUTH編，『最新 創薬化学 上巻』，株式会社テクノミック，1998年08月15日，235-271頁，13章 等価置換に基づく分子の変換 |
| 野崎正勝 等，創薬化学，第１版，株式会社化学同人，1995年，p.98-99 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3093706A1 (en) | 2019-09-26 |
| CN111936144A (zh) | 2020-11-13 |
| WO2019182924A1 (en) | 2019-09-26 |
| EP3768272A4 (en) | 2021-08-11 |
| US20210053943A1 (en) | 2021-02-25 |
| EP3768272B1 (en) | 2025-07-30 |
| EP3768272A1 (en) | 2021-01-27 |
| AU2019237991B2 (en) | 2025-01-02 |
| JP2021518379A (ja) | 2021-08-02 |
| CN111936144B (zh) | 2023-12-22 |
| AU2019237991A1 (en) | 2020-10-15 |
| US11365188B2 (en) | 2022-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7462951B2 (ja) | Ｊａｋ阻害剤 | |
| CA3013618C (en) | Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors | |
| DK2989106T3 (en) | CONDENSED HETEROCYCLIC COMPOUNDS AS PROTEINKINASE INHIBITORS | |
| JP7793529B2 (ja) | Ｋｃｃ２調節剤としての縮合ピリミジン化合物 | |
| AU2018392616B2 (en) | Quinazolinones as PARP14 inhibitors | |
| CN116528864A (zh) | 杂芳基甲酰胺化合物 | |
| US10933063B2 (en) | Bruton's tyrosine kinase inhibitors | |
| WO2017066014A1 (en) | Bruton's tyrosine kinase inhibitors | |
| AU2015320142B2 (en) | Novel imidazopyridazine compounds and their use | |
| KR20120135270A (ko) | 피리도［3,2-ｄ］피리미딘 ｐｉ3ｋ 델타 억제제 화합물 및 이의 용도 | |
| CN104837844B (zh) | 作为酪蛋白激酶1 d/e抑制剂的吡唑取代的咪唑并哌嗪 | |
| JP7660800B2 (ja) | Ｂｔｋ阻害剤としての化合物およびその製造方法と応用 | |
| JP2022517280A (ja) | ブルトン型チロシンキナーゼ阻害剤 | |
| KR20230157432A (ko) | 야누스 키나아제 억제제로서 헤테로사이클릭 유도체 | |
| CN109721600B (zh) | 一类含氮稠环化合物及其制备方法和用途 | |
| CN102656172B (zh) | 8-氧代二氢嘌呤衍生物 | |
| CN111808077B (zh) | 哌嗪酰胺衍生物，其制备方法及其在医药上的用途 | |
| CN111763217B (zh) | 一类噻吩并氮杂环类化合物、制备方法和用途 | |
| CN113943251B (zh) | 双环庚烯基氨基取代的氮杂芳环类化合物及其医药用途 | |
| WO2026060099A1 (en) | Selective pi3k inhibitors | |
| CN115703783A (zh) | 吡咯并嘧啶类衍生物及其制备方法和用途 | |
| HK40078112B (zh) | 氮杂稠环酰胺类化合物及其用途 | |
| HK1232524B (zh) | 新的咪唑并哒嗪类化合物及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220318 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220318 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230208 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230214 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230512 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230822 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231220 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20231221 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20240116 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240312 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240319 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7462951 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |